Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

The team categorized pediatric obesity treatment response, based on changes in body mass index standard deviation score, as ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

When children with obesity undergo weight-loss treatment, the effects have repercussions later in life and the risk of serious health problems and premature death is lower as they reach young ...

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...

Compared with poor response, good response to obesity treatment was associated with lower risk of type 2 diabetes (adjusted ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Novo Nordisk has shared positive headline results from a late-stage study evaluating a higher dose of its GLP-1 receptor ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues, including ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...